University Hospital St. Marina

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

Patrick Marcellin, E. Jenny Heathcote, Ed Gane et al. · New England Journal of Medicine · 2008 · 1.2K citations · Full text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

E. Jenny Heathcote, Patrick Marcellin, Edward Gane et al. · Gastroenterology · 2010 · 461 citations · Full text

Hepatology, Viral Hepatitis, Medicine +8

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

John Pasi, Savita Rangarajan, Pencho Georgiev et al. · New England Journal of Medicine · 2017 · 345 citations · Full text